Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CASA: Adjuvant Pegylated Liposomal Doxorubicin in Older Women With Endocrine Nonresponsive Breast Cancer
NCT00296010Phase 3Terminated
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Aug 2005
- Primary completion
- Dec 2011
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of pegylated liposomal doxorubicin in breast cancer (4 arms), sponsored by ETOP IBCSG Partners Foundation. Primary endpoint: Breast Cancer Free Interval at 5 years. Started Aug 2005; status: terminated.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00296010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00296010.